

School of Optometry

School Seminar

Dr. Tim Lam

Ph.D., FARVO

Senior Director
Pharmacology & Toxicology
Oligasis, United States

Next Generation of Biologics for Treatment of Choroid Neovascularization

Date : **Tuesday 10 November 2015**
Time : **1:00pm – 2:00pm**
Venue : **Room HJ210, The Hong Kong Polytechnic University**
Credit Hour : **1**

Abstract

Age-related macular degeneration (AMD) is one of the leading causes of blindness in developed countries. Neovascular/wet AMD can progress to blindness rapidly. Current anti-vascular endothelial growth factor (VEGF) therapy requires frequent intravitreal injections. Understanding of the pathology of the disease and from anti-angiogenic therapy in cancer suggests the benefit of targeting multiple targets including platelet-derived growth factor (PDGF). With the promising preliminary clinical data from treating patients with anti-PDGF on top of anti-VEGF and the advance of antibody/protein engineering, the desirable next generation biologics could be dual function with prolonged actions. Kodiak Sciences' pipeline molecule, a bioconjugate, shows dual anti-PDGF and anti-VEGF activities and long resident time in ocular tissues with good safety profile.

For enquiry, please contact Ms Winnie Hui at 2766 4323 or by email winnie.hui@polyu.edu.hk

